5 clinical advances and related implications from ESMO 2025

5 particularly insightful takeaways from this year’s ESMO Congress that merit deeper reflection on where cancer care can go.

Advances in breast cancer: What’s new from ESMO 2025

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies worldwide.

ESMO 2025 commences: ADCs, AI, and Asia

ESMO 2025 has kicked off, with an opening press conference focused on early setting ADCs, the potential of AI in oncology, and new drugs from Asia.

BioNTech’s ASCO 2025 oncology advances: New data on bispecif...

At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.

AbbVie’s ASCO 2025 ADC breakthroughs: Transforming oncology ...